Telo Genomics Corp (TELO) Price & Analysis

Compare

21 Followers

TELO Stock Chart & Stats

C$0.04

C$0.01(8.00%)

At close: Jan 07 4:00 PM EST

C$0.04

C$0.01(8.00%)

Day’s Range― - ―

52-Week RangeC$0.04 - C$0.13

Previous CloseN/A

Volume60.50K

Average Volume (3M)29.30K

Market Cap

C$5.02M

Enterprise ValueC$5.04M

Total Cash (Recent Filing)C$486.51K

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding100,430,470

10 Day Avg. Volume22,350

30 Day Avg. Volume29,304

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)18.74

Price to Sales (P/S)0.00

P/FCF Ratio-4.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Single-chromosome Telomere PlatformTelo’s single-chromosome telomere measurement platform is a technical moat that addresses niche clinical and research needs. Durable competitive advantage: specialized measurement capability can enable unique data, partnerships, and licensing opportunities once clinical utility and adoption scale.

Very Low Leverage / No DebtZero reported debt reduces fixed financial obligations and insolvency risk, giving management flexibility to prioritize R&D and validation. Over a multi-month horizon this structural conservatism preserves runway options and lowers creditor pressure during commercialization efforts.

R&D And Clinical Validation MomentumActive MRD presentations and multi-center validation create durable clinical evidence that underpins future commercial adoption. Building robust validation across sites improves credibility with clinicians, payers and partners and materially strengthens the path to revenue once assays are commercialized.

Bears Say

Pre-revenue With Persistent LossesBeing pre-revenue with recurring operating losses means the business lacks internal cash generation and must rely on external funding. This structural gap increases dilution and constrains long-term strategic options until consistent revenue and margins are established.

Shift To Slightly Negative Shareholders' EquityNegative trailing-twelve-month equity signals accumulated losses and/or dilution have eroded the capital base. This weakens balance sheet resilience, limits non-dilutive financing alternatives, and raises the bar for investor confidence over the medium term.

Persistent Negative Operating And Free Cash FlowMaterial negative operating and free cash flow represent an ongoing funding drain that must be covered with new capital. Structurally, sustained cash burn shortens runway, pressures R&D timelines, and makes strategic execution contingent on frequent financing or partner deals.

Telo Genomics Corp News

Telo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing

Telo Genomics Corp ( ($TSE:TELO) ) has shared an announcement. Telo Genomics Corp. has closed the first tranche...

2d ago

Telo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price

Telo Genomics Corp ( ($TSE:TELO) ) has issued an update. Telo Genomics Corp. has appointed John Price as...

22d ago

Telo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing

Telo Genomics Corp ( ($TSE:TELO) ) has shared an update. Telo Genomics Corp. has launched a non-brokered private...

1M ago

Telo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study

Telo Genomics Corp ( ($TSE:TELO) ) just unveiled an update. Telo Genomics has launched a retrospective, blood-based multiple...

2M ago

Telo Genomics Unveils Innovative Myeloma Testing at ASH Meeting

Telo Genomics Corp ( ($TSE:TELO) ) just unveiled an announcement. Telo Genomics Corp. presented its innovative approach to...

2M ago

Telo Genomics Unveils Advanced MRD Technology at Myeloma Summit

Telo Genomics Corp ( ($TSE:TELO) ) has issued an announcement. Telo Genomics Corp. announced its participation in the...

3M ago

Telo Genomics’ MRD Technology Gains Recognition at ASH 2025

Telo Genomics Corp ( ($TSE:TELO) ) has provided an update. Telo Genomics announced that its abstract on telomere-based...

4M ago

Telo Genomics Expands with New Toronto Facility and Board Update

The latest update is out from Telo Genomics Corp ( ($TSE:TELO) ). Telo Genomics Corp has relocated its...

5M ago

Telo Genomics Unveils Innovative MRD Methodology at Myeloma Society Meeting

An announcement from Telo Genomics Corp ( ($TSE:TELO) ) is now available. Telo Genomics Corp presented a new...

5M ago

Telo Genomics Engages Hayden IR for Investor Relations Enhancement

An announcement from Telo Genomics Corp ( ($TSE:TELO) ) is now available. Telo Genomics Corp. has engaged Hayden...

5M ago

TELO FAQ

What was Telo Genomics Corp’s price range in the past 12 months?

Telo Genomics Corp lowest stock price was C$0.04 and its highest was C$0.13 in the past 12 months.

What is Telo Genomics Corp’s market cap?

Telo Genomics Corp’s market cap is C$5.02M.

When is Telo Genomics Corp’s upcoming earnings report date?

Telo Genomics Corp’s upcoming earnings report date is Mar 03, 2026 which is in 11 days.

How were Telo Genomics Corp’s earnings last quarter?

Currently, no data Available

Is Telo Genomics Corp overvalued?

According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Telo Genomics Corp pay dividends?

Telo Genomics Corp does not currently pay dividends.

What is Telo Genomics Corp’s EPS estimate?

Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Telo Genomics Corp have?

Telo Genomics Corp has 100,430,470 shares outstanding.

What happened to Telo Genomics Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Telo Genomics Corp?

Currently, no hedge funds are holding shares in TSE:TELO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Telo Genomics Corp

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.